Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FEMASYS INCFEMY · Entity 7510 | Chief Clinical-Medical Affairs | August 07, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FEMASYS INC
Report date August 07, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,125 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 3,125 · Balance 3,125 F1: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2029-08-10 | Direct | 3,125 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Grant · Acquired 3,125 · Balance 3,125 F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4: The reported securities were purchased by the reporting person for an aggregate amount of $10,000. F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. |
| Common Stock Purchase Warrant (Milestone)SEC Table II · derivative / convertible security · Conversion / exercise price $2.95 | Direct | 3,125 |
Reported balance
After 2026-08-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-07 · Grant · Acquired 3,125 · Balance 3,125 F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4: The reported securities were purchased by the reporting person for an aggregate amount of $10,000. F5: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
F2: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
F3: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
F4: The reported securities were purchased by the reporting person for an aggregate amount of $10,000.
F5: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 12, 2026 00:54 UTC | FEMASYS INC FEMY · Entity 7510 | GrantCommon Stock Purchase Warrant (Milestone) · Derivative | 3,125 | Not disclosed Strike: $2.95 | Not disclosed |
DisclosureSEC source: 0001140361-26-032336 · form4.xml · derivative · entry 3 Mifek Jeffrey Gerald · CIK 0002143295 · Chief Clinical-Medical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125 Underlying: Common stock, par value $0.001 per share · 3,125 shares Expires not disclosed F2 · derivative.exercise_price: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4 · price: The reported securities were purchased by the reporting person for an aggregate amount of $10,000. F5 · derivative.exercise_date: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F5 · derivative.expiration_date: The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable. F3 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| August 07, 2026 Filed Aug 12, 2026 00:54 UTC | FEMASYS INC FEMY · Entity 7510 | GrantCommon Stock Purchase Warrant · Derivative | 3,125 | Not disclosed Strike: $2.95 | Not disclosed |
DisclosureSEC source: 0001140361-26-032336 · form4.xml · derivative · entry 2 Mifek Jeffrey Gerald · CIK 0002143295 · Chief Clinical-Medical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125 Underlying: Common stock, par value $0.001 per share · 3,125 shares Expires 2029-08-10 F2 · derivative.exercise_price: Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. F4 · price: The reported securities were purchased by the reporting person for an aggregate amount of $10,000. F3 · derivative.underlying_shares: The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. Read SEC document |
| August 07, 2026 Filed Aug 12, 2026 00:54 UTC | FEMASYS INC FEMY · Entity 7510 | PurchaseCommon Stock | 3,125 | $3.20 | $10,000.00 |
DisclosureSEC source: 0001140361-26-032336 · form4.xml · nonDerivative · entry 1 Mifek Jeffrey Gerald · CIK 0002143295 · Chief Clinical-Medical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125 F1 · price: The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto. Read SEC document |
| July 06, 2026 Filed Aug 12, 2026 00:51 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001140361-26-032332 · form4.xml · derivative · entry 1 Mifek Jeffrey Gerald · CIK 0002143295 · Chief Clinical-Medical Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2036-07-06 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on July 6, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.